Fast Track for Epidiolex

The FDA designates GW Pharmaceuticals' (GWPH) cannabidiol product Epidiolex Fast Track for the treatment fo Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. Earlier, the agency designated Epidiolex an Orphan Drug for this indication in addition to Lennox-Gastaut (LGS) syndrome.

The company expects to hold a pre-IND meeting with the FDA in the next few months and will conduct two Phase 3 clinical trials in LGS in 2015.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs